U-Factor Holdings Commences Joint Research with The University of Tokyo Hospital to Develop Drugs from Stem Cell Culture Supernatant 'U-Factor® Liquid'

U-Factor Holdings Co., Ltd. announced a joint research agreement with the Department of Geriatric Medicine at The University of Tokyo Hospital, signed on April 14, 2026. The research aims to elucidate the regulatory mechanisms of extracellular vesicles and stem cell secretomes on aging-related diseases like sarcopenia. U-Factor will provide its proprietary stem cell culture supernatant, 'U-Factor® Liquid', to investigate its efficacy using cellular and animal models. This collaboration seeks to build a scientific foundation for drug discovery addressing the growing medical needs of an aging population without established pharmacological treatments.